Skip to main content
Clinical Trials/NCT01097733
NCT01097733
Completed
N/A

Dual-Source Computed Tomography to Improve Prediction of Response to Cardiac Resynchronization Therapy

Massachusetts General Hospital1 site in 1 country38 target enrollmentFebruary 2009

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure - NYHA II - IV
Sponsor
Massachusetts General Hospital
Enrollment
38
Locations
1
Primary Endpoint
Clinical Response to CRT
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Cardiac Resynchronization Therapy (CRT) is a widely accepted treatment that has led to improved clinical outcomes for patients with refractory congestive heart failure (CHF), systolic dysfunction, and wide QRS duration. However, it requires implantation of an expensive device ($30,000) and about 1/3 of patients do not have clinical improvement. Inadequate amounts of LV dyssynchrony or suboptimal lead placement may limit clinical response. Dual-Source computed tomography (DSCT) allows for subtle detection during myocardial contraction for assessing LV dyssynchrony, and can also assess coronary venous anatomy and scar burden. Thus DSCT may be the ideal noninvasive modality to predict response to CRT.

Registry
clinicaltrials.gov
Start Date
February 2009
End Date
January 2012
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jagmeet Singh

Jagmeet Singh, MD

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Older than 18 years of age
  • Ability to provide informed consent
  • Planned CRT implantation
  • NYHA Functional Class II-IV heart failure
  • Echo Ejection Fraction less than or equal to 35%
  • QRS duration greater than or equal to 120 ms
  • Normal or mildly reduced kidney function (estimated serum creatinine less than or equal to 1.5 mg/dL or less than or equal to 1.3 mg/dL for diabetic subjects on metformin
  • For diabetic subjects on glucophage (metformin) they will be required to stop glucophage (metformin) for at least 48 hours after the administration of contrast.

Exclusion Criteria

  • Known allergy to iodine or iodinated contrast
  • Chronic persistent atrial fibrillation
  • Pregnancy or unknown pregnancy status
  • Subjects on glucophage (metformin) therapy that are unable or unwilling to discontinue therapy for 48 hours after CT scan
  • Known inadequate venous access for appropriate IV caliber placement
  • Iodinated contrast administration within the past 48 hours
  • Subjects who cannot hold their breath for 10-15 seconds

Outcomes

Primary Outcomes

Clinical Response to CRT

Time Frame: 6 months post implantation of CRT

The clinical response to CRT will be adjudicated by two experienced cardiologists taking into account left ventricular ejection fraction, NYHA functional class, and patient global assessment score.

Secondary Outcomes

  • Major adverse cardiovascular events (MACE)(2 years)
  • Secondary endpoints(6 months)

Study Sites (1)

Loading locations...

Similar Trials